A multicenter phase 3 trial comparing ocrelizumab to fingolimod for children with MS achieved its noninferiority primary ...
6don MSN
Diabetes drug and antihistamine could together repair multiple sclerosis damage, trial finds
A combination of metformin, a common diabetes drug, and clemastine, an antihistamine, can help repair myelin—the protective ...
Germany is the first European country to launch the product, with further rollouts across Europe to followThe next-generation ...
Topline trial data showed that a higher Ocrevus dose didn't provide more benefit than the standard regimen in people with ...
Vidofludimus calcium reduced the risk of confirmed disability worsening in people with progressive and relapsing forms of MS, ...
Breakthrough T1D (formerly JDRF), the Lupus Research Alliance, and the National Multiple Sclerosis Society today announce the ...
Everyday Health on MSN
6 Frequently Asked Questions About Inactive Secondary-Progressive MS, Answered
Having inactive secondary progressive multiple sclerosis can be confusing. Relapses may stop, but symptoms persist. Get ...
10don MSN
Machine learning and cell imaging combine to predict effectiveness of multiple sclerosis medication
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will ...
News-Medical.Net on MSN
Researchers develop tool to predict how patients will respond to common multiple sclerosis drug
Brazilian researchers, in partnership with French institutions, have developed a tool that can predict how patients will ...
The 51-mile Multiple Steps for Multiple Sclerosis (MS4MS) walk, led by Jessica Fincham from north Hampshire, raised £58,000 for the MS Society’s Stop MS Appeal. Jessica said: "It has been an ...
Jessica Fincham, 50, from North Hampshire, finished the walk on September 21, raising £58,000 for the MS Society through her "Multiple ...
Neuraxpharm participates in ECTRIMS, reinforcing its commitment to multiple sclerosis Barcelona, Spain and Düsseldorf, Germany – September 22, 2025 – Neuraxpharm Group (Neuraxpharm), a leading ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results